medigraphic.com
Medicina Universitaria

2008, Number 41

<< Back Next >>

Med Univer 2008; 10 (41)

Human papilloma virus (HPV) infection in women with rheumatoid arthritis

Flores ADE, Ortiz LR, Garza EMA, Rodríguez AJ, Vázquez FBR, González BA

Language: Spanish
References: 47
Page: 205-211
PDF size: 303.48 Kb.


ABSTRACT

Background: Human papillomavirus (HPV) is the main risk factor for the development of cervical cancer, which remains the most common malignancy in our country. There are studies in which immunosuppressed patients have an increased risk of suffering an infection by HPV.
Objective: To determine the prevalence of HPV infection in patients with rheumatoid arthritis (RA) compared with women matched by age in an open population.
Materials and methods: A cross-sectional, comparative, and observational study in women with RA and women without rheumatic disease to whom cervical cytology, HPV detection and typing were performed. Data were analyzed using Chi2 test, Fisher’s exact, Mann-Whitney and odds ratio.
Results: The study included 77 women with RA matched by age and 77 women without RA. The frequency of HPV infection in 37 patients with RA (48%) against 17 women without RA (22%) [OR 3.1551 95% (1.56 - 6.35) p = 0,001]. HPV types 83 and 59 were more frequent in women with RA, while in the controls, types 59, 81 and 54 were found. No relation with the duration of the disease, steroid use, or immunosuppression was found.
Conclusions: HPV infection is more common in women with rheumatoid arthritis compared to those women without rheumatic disease.


REFERENCES

  1. Melkert PW, Hopman E, van den Brule AJ, Risse EK, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;1(53):919-23.

  2. Basil JB, Horowitz IR. Cervical carcinoma: contemporary management. Obstet Gynecol Clin North Am 2001;28:727-42.

  3. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003;9:348-59.

  4. Monsonego J, Bosch FX, Coursaget P, Cox JT, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2003;108:329-33.

  5. Zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986;2:489-91.

  6. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002;89:183-90.

  7. Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003:20-28.

  8. Franco EL. Measurement errors in epidemiological studies of human papillomavirus and cervical cancer. IARC Sci Publ 1992:181-97.

  9. Franco EL. Viral etiology of cervical cancer: a critique of the evidence. Rev Infect Dis 1991;13:1195-206.

  10. Burk RD, Ho GY, Beardsley L, Lempa M, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996;174:679-89.

  11. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102;3-8.

  12. Nyari TA, Kalmar L, Deak J, Szollosi J, et al. Prevalence and risk factors of human papilloma virus infection in asymptomatic women in southeastern Hungary. Eur J Obstet Gynecol Reprod Biol 2004;115:99-100.

  13. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

  14. Unger ER, Duarte-Franco E. Human papillomaviruses: into the new millennium. Obstet Gynecol Clin North Am 2001;28:653,66,vii-viii.

  15. Ghaderi M, Nikitina Zake L, Wallin K, Wiklund F, et al. Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum Immunol 2001;62:1153-8.

  16. Ghaderi M, Wallin KL, Wiklund F, Zake LN, et al. Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes. Int J Cancer 2002;100:698-701.

  17. Giuliano AR, Siegel EM, Roe DJ, Ferreira S, et al. Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study. J Infect Dis 2003;188:1508-16.

  18. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. The interval between menarche and age of first sexual intercourse as a risk factor for subsequent HPV infection in adolescent and young adult women. J Pediatr 2002;141:718-23.

  19. Pham TH, Nguyen TH, Herrero R, Vaccarella S, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer. 2003;104:213-20.

  20. Matos E, Loria D, Amestoy GM, Herrera L, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30:593-9.

  21. Torroella-Kouri M, Morsberger S, Carrillo A, Mohar A, et al. HPV prevalence among Mexican women with neoplastic and normal cervixes. Gynecol Oncol 1998;70:115-20.

  22. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.

  23. Munoz N, Bosch FX, de Sanjose S, Herrero R, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.

  24. Albrecht V, Chevallier A, Bongan A, Lefebvre JC, Giordanengo V. Immunohistochemical and molecular study of severe cervical dysplasia associated with HPV-83. Gynecol Oncol 2007;105:252-5

  25. Liaw KL, Hsing AW, Chen CJ, Schiffman MH, et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995;62:565-71.

  26. Liaw KL, Hildesheim A, Burk RD, Gravitt P, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.

  27. Ho GY, Burk RD, Klein S, Kadish AS, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.

  28. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 2003;169:431-4.

  29. Kay S, Frable WJ, Hume DM. Cervical dysplasia and cancer developing in women on immunosuppression therapy for renal homotransplantation. Cancer 1970;26:1048-52.

  30. Sillman F, Stanek A, Sedlis A, Rosenthal J, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984;150:300-8.

  31. Sun XW, Kuhn L, Ellerbrock T. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.

  32. Kelly HB. Pathogenesis of sysytemic lupus erythematosus. Textbook of Rheumatology. Vol. 1. 5th ed. Philadelphia: Saunders, 2004:1015-27.

  33. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394-400.

  34. Dhar JP, Kmak D, Bhan R, Pishorodi L, et al. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001;82:4-6.

  35. Berthier S, Mougin C, Vercherin P, Desmurs H, et al. Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 1999;20:128-32.

  36. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000;9:542-4.

  37. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum 1981;24:648-50.

  38. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994;3:59-61.

  39. Tam LS, Chan AYK, Chan PKS. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50:3619-25.

  40. Chakravarty E, Genovese MC. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 2003;15:35-43.

  41. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004;16:254-61.

  42. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.

  43. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50.

  44. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.

  45. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.

  46. Rojo CEW, González LL, Montoya FH. Prevalencia y factores asociados con infección por el virus del papiloma humano cervical en artritis reumatoide. Reumatol Clin 2007;3(Suppl 1):12.

  47. Albrecht V, Chevallier A, Bongan A, Lefebvre JC, Giordanengo V. Immunohistochemical and molecular study of severe cervical dysplasia associated with HPV-83. Gynecol Oncol 2007;105:252-5.




2020     |     www.medigraphic.com